The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. The coprimary end points were the cumulative incidences of new vertebral fractures at 12 months and 24 months. Secondary end points included clinical (a composite of nonvertebral and symptomatic vertebral) and nonvertebral fractures. RESULTS: At 12 months, new vertebral fractures had occurred in 16 of 3321 patients (0.5%) in the romosozumab group, as compared with 59 of 3322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab; P<0.001). Clinical fractures had occurred in 58 of 3589 patients (1.6%) in the romosozumab group, as compared with 90 of 3591 (2.5%) in the placebo group (a 36% lower risk with romosozumab; P=0.008). Nonvertebral fractures had occurred in 56 of 3589 patients (1.6%) in the romosozumab group and in 75 of 3591 (2.1%) in the placebo group (P=0.10). At 24 months, the rates of vertebral fractures were significantly lower in the romosozumab group than in the placebo group after each group made the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group. CONCLUSIONS: In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It achieves this by upregulating the Wnt pathway while also acting as an enhancer of RANKL synthesis, thereby downregulating this latter pathway [83,84,85].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it uniquely exhibits the ability to stimulate bone formation while simultaneously reducing bone resorption.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Romosozumab is a newly approved monoclonal antibody targeting sclerostin.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A systematic review of hip fracture incidence and probability of fracture worldwide
Kanis, J. A., Odén, A., McCloskey, E. V., Johansson, H., Wahl, D. A., Cooper, C. C., & on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) · Osteoporosis International · doi:10.1007/s00198-012-1964-3 · Cited by 1,382
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Estimating Hip Fracture Morbidity, Mortality and Costs
Braithwaite, R. S., Col, N. F., & Wong, J. B. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51110.x · Cited by 915
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
Kuo, T.-H., Lin, W., Chao, J.-Y., Wu, A., Tseng, C., Chang, Y., Liou, H., & Wang, M.-C. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1452-5 · Cited by 32
Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23
Mäkitie, R. E., Kämpe, A. J., Costantini, A., Alm, J. J., Magnusson, P., & Mäkitie, O. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3959 · Cited by 34
Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis
Ahn, T., Kim, K., Joshi, H. P., Park, K. H., Kyung, J. W., Choi, U. Y., Sohn, S., Sheen, S. H., Shin, D.-E., Lee, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124274 · Cited by 33
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis
Prather, C., Adams, E. N., & Zentgraf, W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa285 · Cited by 35
Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020
Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J., Vellas, B. J., & Cruz-Jentoft, A. J. (2021) · The Journal of Frailty & Aging · doi:10.14283/jfa.2021.4 · Cited by 36
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 35
Frysz, M., Gergei, I., Scharnagl, H., Smith, G. D., Zheng, J., Lawlor, D. A., Herrmann, M., Maerz, W., & Tobias, J. H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4467 · Cited by 33
Georgakopoulou, E. A., Stebbing, J., & Scully, C. M. (2018) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2017.08.046 · Cited by 33
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 34
SEIOMM Working Group, Guañabens, N., Moro-Álvarez, M. J., Casado, E., Blanch‐Rubió, J., Gómez‐Alonso, C., Diaz‐Guerra, G. M., del Pino‐Montes, J., Valero, C., Peris, P., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01919-8 · Cited by 33
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis
Saag, K. G., Petersen, J., & Grauer, A. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1714810 · Cited by 33
Self-citationThe osteoblast in regulation of tumor cell dormancy and bone metastasis
Zarrer, J., & Taipaleenmäki, H. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100597 · Cited by 32
The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans
Boudin, E., Yorgan, T. A., Fijałkowski, I., Sonntag, S., Steenackers, E., Hendrickx, G., Peeters, S., Maré, A. D., Vervaet, B. A., Verhulst, A., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3160 · Cited by 33
Long-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 33
Self-citationMovérare‐Skrtic, S., Nilsson, K. H., Henning, P., Funck‐Brentano, T., Nethander, M., Rivadeneira, F., Nunes, G. C., Koskela, A., Tuukkanen, J., Tuckermann, J. P., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900707r · Cited by 32
Zheng, J., Maerz, W., Gergei, I., Kleber, M. E., Drechsler, C., Wanner, C., Brandenburg, V. M., Reppe, S., Gautvik, K. M., Medina‐Gómez, C., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3803 · Cited by 33
Cardinal, M., Dessain, A., Roels, T., Lafont, S., Ominsky, M. S., Devogelaer, J., Chappard, D., Mabilleau, G., Ammann, P., Behets, C., et al. (2020) · Calcified Tissue International · doi:10.1007/s00223-019-00655-5 · Cited by 32
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Kim, B., Lee, S. H., & Koh, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.55 · Cited by 34
Rodríguez, A. J., Ernst, M., Nybo, M., Prieto‐Alhambra, D., Ebeling, P. R., Hermann, A. P., & Abrahamsen, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa481 · Cited by 32
Sacco, R., Woolley, J., Patel, G., Calasans‐Maia, M. D., & Yates, J. M. (2021) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2021.03.006 · Cited by 32
Holdsworth, G., Staley, J. R., Hall, P., van Koeverden, I. D., Vangjeli, C., Okoye, R., Boyce, R. W., Turk, J. R., Armstrong, M., Wolfreys, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4287 · Cited by 32
Kim, H. Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1170 · Cited by 34
Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment
Tominaga, A., Wada, K., Okazaki, K., Nishi, H., Terayama, Y., Kodama, Y., & Kato, Y. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06261-2 · Cited by 32
Iron metabolism and ferroptosis in diabetic bone loss: from mechanism to therapy
Bao, J., Yan, Y., Zuo, D., Zhuo, Z., Sun, T., Lin, H., Han, Z., Zhao, Z., & Yu, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1178573 · Cited by 33
Løbo, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00014-7 · Cited by 33
Lau, E. M. C., Dinavahi, R. V., Woo, Y. C., Wu, C., Guan, J., Maddox, J., Tolman, C., Yang, W., & Shin, C. S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05324-0 · Cited by 32
Self-citationAbaloparatide Is an Anabolic, but Does It Spare Resorption?
Martin, T. J., & Seeman, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3042 · Cited by 31
Genetic approaches to metabolic bone diseases
Hannan, F. M., Newey, P. J., Whyte, M. P., & Thakker, R. V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13803 · Cited by 32
Kuroshima, S., Sasaki, M., Murata, H., & Sawase, T. (2019) · Gerodontology · doi:10.1111/ger.12416 · Cited by 32
Sato, T., Verma, S. K., Khatri, A., Dean, T., Göransson, O., Gardella, T. J., & Wein, M. N. (2020) · JBMR Plus · doi:10.1002/jbm4.10441 · Cited by 29
Tian, A., Jia, H., Zhu, S., Lü, B., Li, Y., Ma, J., & Ma, X. (2021) · Orthopaedic Surgery · doi:10.1111/os.13136 · Cited by 31
Therapeutics for enhancement of spinal fusion: A mini review
Zhang, Y., Jiang, Y., Zou, D., Yuan, B., Ke, H. Z., & Li, W. (2021) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2021.11.001 · Cited by 31
Hadaya, D., Gkouveris, I., Soundia, A., Bezouglaia, O., Boyce, R. W., Stolina, M., Dwyer, D., Dry, S., Pirih, F. Q. M., Aghaloo, T. L., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3581 · Cited by 31
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review
Orsini, F., Crotti, C., Cincinelli, G., Taranto, R. D., Amati, A., Ferrito, M., VARENNA, M., & Caporali, R. F. (2023) · Biology · doi:10.3390/biology12101320 · Cited by 31
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
Bauer, D. C., Black, D. M., Dell, R., Fan, B., Smith, C., Ernst, M. T., Jurik, A. G., Frøkjær, J. B., Boesen, M., Vittinghoff, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae023 · Cited by 30
Current therapeutic approach of chronic kidney disease‐mineral and bone disorder
Zaimi, M., & Grapsa, E. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14177 · Cited by 31
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 35
Romosozumab for the treatment of osteoporosis – a systematic review
Mäkinen, V.-N., Sølling, A. S., McClung, M. R., & Langdahl, B. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02469-1 · Cited by 32
Fontalis, A., Kenanidis, E. I., Kotronias, R. A., Papachristou, A., Anagnostis, P. G., Potoupnis, M. E., & Tsiridis, E. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594772 · Cited by 31
Atypical femoral fractures from bisphosphonate in cancer patients – Review
Lockwood, M. B., Banderudrappagari, R., Suva, L. J., & Makhoul, I. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100259 · Cited by 30
Hara, T., Hijikata, Y., Matsubara, Y., & Watanabe, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013424.pub2 · Cited by 31
Wu, R., Lian, W., Chen, Y., Ko, J., Wang, S.-Y., Jahr, H., & Wang, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179476 · Cited by 30
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
Poole, K. E. S., Treece, G. M., Pearson, R. A., Gee, A. H., Bolognese, M. A., Brown, J. P., Goemaere, S., Grauer, A., Hanley, D. A., Mautalén, C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4465 · Cited by 30
Self-citationTreating osteoporosis: risks and management
Zhu, J., & MARCH, L. M. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.054 · Cited by 31
Slama, L., Porcher, R., Linard, F., Chakvetadze, C., Cros, A., Carillon, S., Gallardo, L., Viard, J., & Molina, J. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08071-9 · Cited by 30
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 35
Everts‐Graber, J., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Sromek, K., Schmid, G., Gahl, B., Häuselmann, H., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07155-9 · Cited by 29
Zheng, Y., Li, J., Li, Y., Wang, J., Suo, C., Jiang, Y., Li, J., Xu, K., & Chen, X. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.019 · Cited by 32
Cook, B. D., Rafiq, R., Lee, H., Banks, K. M., El-Debs, M., Chiaravalli, J., Glickman, J. F., Das, B. C., Chen, S., & Evans, T. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.03.009 · Cited by 29
Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study
Resulaj, M., Polineni, S. P., Meenaghan, E. M., Eddy, K. T., Lee, H., & Fazeli, P. K. (2019) · JBMR Plus · doi:10.1002/jbm4.10251 · Cited by 29
Kashii, M., Ebina, K., Kitaguchi, K., & Yoshikawa, H. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100288 · Cited by 30
The endocrine role of bone: Novel functions of bone-derived cytokines
Wang, H., Zheng, X.-Q., Zhang, Y., Huang, J., Zhou, W., Li, X., Tian, H., Wang, B., Xing, D., Fu, W., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114308 · Cited by 31
The pathophysiology of immunoporosis: innovative therapeutic targets
Ferbebouh, M., Vallières, F., Benderdour, M., & Fernandes, J. (2021) · Inflammation Research · doi:10.1007/s00011-021-01484-9 · Cited by 31
Lin, S., Hung, M.-C., Chang, S., Tsuang, F.-Y., Chang, J. Z., & Sun, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143043 · Cited by 30
Zhang, S., Xie, D., & Zhang, Q. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105851 · Cited by 31
Kobayakawa, T., Miyazaki, A., Takahashi, J. A., & Nakamura, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116480 · Cited by 30
Riancho, J., Peris, P., González-Macı́as, J., & Pérez-Castrillón, J.-L. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000100003 · Cited by 36
Management of bone loss due to endocrine therapy during cancer treatment
Khan, M. I. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06672-3 · Cited by 30
Gobron, B., Couchot, M., Irwin, N., Legrand, É., Bouvard, B., & Mabilleau, G. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4792 · Cited by 29
Zhao, N., Li, Q., Wang, Y., Qiao, Q., Huang, H., Guo, C.-B., & Guo, Y. (2023) · BMC Oral Health · doi:10.1186/s12903-023-03034-7 · Cited by 29
A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence
Ward, L. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1266986 · Cited by 29
Advances in strontium-releasing biomaterials for bone repair
Mehta, D., & Gentleman, E. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123718 · Cited by 28
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea
Chou, S. H.-H., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.009 · Cited by 28
Molecular understanding of pharmacological treatment of osteoporosis
Tanaka, S. (2019) · EFORT Open Reviews · doi:10.1302/2058-5241.4.180018 · Cited by 28
Taylor, A. D., & Saag, K. G. (2019) · Core evidence · doi:10.2147/ce.s172820 · Cited by 28
Roles of Dkk2 in the Linkage from Muscle to Bone during Mechanical Unloading in Mice
Kawao, N., Morita, H., Iemura, S., Ishida, M., & Kaji, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072547 · Cited by 31
Baek, K., Chung, Y., Koh, J., Kim, I. J., Kim, K. M., Min, Y., Park, K. D., Dinavahi, R. V., Maddox, J., Yang, W., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.848 · Cited by 28
Self-citationGPR35 regulates osteogenesis via the Wnt/GSK3β/β-catenin signaling pathway
Zhang, Y., Shi, T., & He, Y. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.084 · Cited by 28
A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders
Formosa, M. M., Bergen, D. J. M., Gregson, C. L., Maurizi, A., Kämpe, A. J., García‐Giralt, N., Zhou, W. Z., Grinberg, D., Ovejero, D., Zillikens, M. C., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.709711 · Cited by 28
Mouse LGR6 regulates osteogenesis in vitro and in vivo through differential ligand use
Khedgikar, V., Charles, J. F., & Lehoczky, J. A. (2021) · Bone · doi:10.1016/j.bone.2021.116267 · Cited by 28
Lu, J., Hu, D., Ma, C., & Shuai, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.938447 · Cited by 29
Recent fall and high imminent risk of fracture in older men and women
Kim, K. M., Lui, L., & Cummings, S. R. (2022) · Age and Ageing · doi:10.1093/ageing/afac141 · Cited by 28
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 28
Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
de Medeiros, M. C. W. C., Rocha, N. D. A., Bandeira, E., Dantas, I., Chaves, C., Oliveira, M., & Bandeira, F. A. F. (2020) · International Journal of Nephrology · doi:10.1155/2020/4596920 · Cited by 28
Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)
Dimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 28
Osteoporosis Therapy: Bone Modeling during Growth and Aging
Sugiyama, T., & Oda, H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00046 · Cited by 27
Anabolic Therapy for the Treatment of Osteoporosis in Childhood
Ward, L. M., & Rauch, F. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0434-z · Cited by 28
Advances and Unmet Needs in the Therapeutics of Bone Fragility
Ramchand, S. K., & Seeman, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00505 · Cited by 26
Fatima, N., Massaad, E., Hadzipasic, M., Shankar, G. M., & Shin, J. H. (2020) · Neurosurgical Review · doi:10.1007/s10143-020-01359-3 · Cited by 29
Papapoulos, S. E., Bone, H. G., Cosman, F., Dempster, D. W., McClung, M. R., Nakamura, T., Restrepo, J. F. M., Bouxsein, M., Cohn, D., de Papp, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4284 · Cited by 28
Self-citationMechanisms of altered bone remodeling in children with type 1 diabetes
Brunetti, G., D’Amato, G., Santis, S. D., Grano, M., & Faienza, M. F. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.997 · Cited by 27
Recommendations by the Spanish Society of Rheumatology on Osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Rodríguez, G. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.09.011 · Cited by 27
Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure
Jung, J., Ryu, J., Shim, G., & Kwon, Y. (2023) · Clinical Oral Implants Research · doi:10.1111/clr.14144 · Cited by 28
Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?
Clemenceau, A., Michou, L., Diorio, C., & Durocher, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228613 · Cited by 27
Romosozumab — Promising or Practice Changing?
Rosen, C. J. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711298 · Cited by 27
Sequential and Long-term Therapy for Osteoporosis
McClung, M. R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00909-2 · Cited by 26
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
Langdahl, B. L., & Andersen, J. D. (2018) · Journal of Bone Metabolism · doi:10.11005/jbm.2018.25.3.133 · Cited by 25
Bhattacharyya, S., Pal, S., Mohamed, R., Singh, P., Chattopadhyay, S., China, S. P., Porwal, K., Sanyal, S., Gayen, J. R., & Chattopadhyay, N. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109207 · Cited by 26
Which treatment to prevent an imminent fracture?
Iconaru, L., Baleanu, F., Charles, A., Mugisha, A., Benoit, F., Surquin, M., Karmali, R., Body, J.-J., & Bergmann, P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101105 · Cited by 26
Aditya, S., & Rattan, A. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_106_20 · Cited by 26
The effect of osteoporosis treatment on bone mass
Appelman‐Dijkstra, N. M., Oei, H. L. D. W., Veldhuis‐Vlug, A. G., & Winter, E. M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101623 · Cited by 27
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., & Okazaki, K. (2022) · Modern Rheumatology · doi:10.1093/mr/roac059 · Cited by 27
Tarantino, U., Cariati, I., Greggi, C., Iundusi, R., Gasbarra, E., Iolascon, G., Kurth, A., Åkesson, K., Bouxsein, M., Leali, P. T., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06482-z · Cited by 26
The role of E3 ubiquitin ligases in bone homeostasis and related diseases
Dong, Y., Chen, Y., Ma, G., & Cao, H. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.016 · Cited by 26
Kawazoe, M., Kaneko, K., Shikano, K., Kusunoki, N., Nanki, T., & Kawai, S. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3689-3 · Cited by 25
Risk factors for imminent fractures: a substudy of the FRISBEE cohort
Iconaru, L., Moreau, M., Baleanu, F., Kinnard, V., Charles, A., Mugisha, A., Surquin, M., Benoit, F., Karmali, R., Paesmans, M., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05772-8 · Cited by 26
Taylor, S., Hu, R., Pacheco, E., Locher, K., Pyrah, I., Ominsky, M. S., & Boyce, R. W. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.03.002 · Cited by 25
Cosman, F., Oates, M. K., Betah, D., Timoshanko, J., Wang, Z., Ferrari, S., & McClung, M. R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae116 · Cited by 29
Self-citation
Metadata
- Authors
- Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., Zerbini, C. A. F., Milmont, C. E., Chen, L., Maddox, J., Meisner, P. D., Libanati, C., & Grauer, A.
- Affiliations
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-20
- Volume
- 375
- Issue
- 16
- Pages
- 1532-1543
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2520995084
- Cited by
- 1,805
- References
- 24
- Citations by year
- 2026: 225 · 2025: 223 · 2024: 219 · 2023: 168 · 2022: 194 · 2021: 192 · 2020: 182 · 2019: 141 · 2018: 131 · 2017: 110 · 2016: 16
- FWCI
- 161.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, osteoporosis, postmenopausal women, vertebral fractures, non-vertebral fractures, denosumab, bone formation, bone resorption, fracture risk reduction, monoclonal antibodies, adverse events, hyperostosis, cardiovascular events, osteoarthritis, cancer risk, RANKL
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
